Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results

Kinoshita, Nozomi; Konno, Yoshihiro; Hamada, Naoki; Kanda, Yoshinobu; Shimmura-Tomita, Machiko; Kakehashi, Akihiro

doi:10.1007/s10384-018-0608-3

Cited by 90 publications

(130 citation statements)

References 47 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Kinoshita has reported that the combined application of 0.01% atropine eye drops and orthokeratology can signi cantly slow the axis elongation compared to the use of orthokeratology alone [20]. A retrospective study also reported similar results [21].…”

Section: Discussionmentioning

confidence: 80%

Efficacy and Safety of Atropine to Control Myopia Progression: A Systematic Review and Meta-analysis

Zhao¹,

Cai²,

Ding

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The effect and safety of atropine on delaying the progression of myopia has been extensively studied, but its optimal effect dose is still unclear. Therefore, the purpose of this meta-analysis is to systematically evaluate the safety and effectiveness of atropine in controlling the progression of myopia, and to explore the relationship between the dose of atropine and the effect of controlling the progression of myopia. Methods: This work was done through the data search from PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The Cochrane Handbook was also used to evaluate the quality of these included studies. In addition, a meta-analysis was performed using Revman5.3 software. Results: A total of 10 randomized controlled trials (RCTs) were included. Myopia progression was mitigated greater in the atropine treatment group than the control group, with MD = -0.80, 95% CI (-0.94, -0.66) during the whole observation period. There was a statistical difference between 0.05%, 0.5%, and 1.0% atropine (P = 0.004). In addition, less axial elongation was showed, with MD = -0.26, 95% CI (-0.33, -0.18) during the whole observation period. Conclusion: The effect of atropine in controlling the progression of myopia was dose related. A 0.05% atropine was likely to be the optimal dose.

show abstract

Section: Discussionmentioning

confidence: 80%

Efficacy and Safety of Atropine to Control Myopia Progression: A Systematic Review and Meta-analysis

Zhao¹,

Cai²,

Ding

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Some practitioners advocate using overnight orthokeratology in young children since the parents can insert and remove the lenses and the children only wear the lenses while at home. Combination therapies have only recent begun to be evaluated, and it is unclear whether the reported increased effectiveness of combining atropine with orthokeratology is due to pharmacology or a larger pupil enhancing the optical effects 146–149 …”

Section: How Will We Manage Myopia 10 Years From Now?mentioning

confidence: 99%

Myopia Control 2020: Where are we and where are we heading?

Bullimore

Richdale

2020

Ophthalmic Physiologic Optic

View full text Add to dashboard Cite

Purpose: This review arms practitioners with the evidence-based information they need to fully manage myopia. Recent findings: The recent peer-reviewed literature is critically evaluated to provide a comprehensive analysis of the safety and efficacy of behavioural, optical and pharmaceutical myopia management. Importantly, the paper addresses not only who to treat, but how to treat them, and when to stop or modify treatments. Finally, the paper discusses expectations for treatment and why slowing myopia by even 1 dioptre improves long term health outcomes. Summary: The management of an individual child should be underpinned by the evidence-based literature and clinicians must stay alert to ongoing myopia research that will undoubtedly result in an evolution of the standard of care for the myopic and pre-myopic child.

show abstract

“…Kinoshita has reported that the combined application of 0.01% atropine eye drops and orthokeratology can significantly slow the axis elongation compared to the use of orthokeratology alone [13]. A retrospective study also reported similar results [14].…”

Section: Combined With Orthokeratologymentioning

confidence: 79%

Efficacy and Safety of Atropine to Control Myopia Progression: a Systematic Review and Meta-analysis

Zhao¹,

Cai²,

Ding

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: To systematically evaluate the safety and effectiveness of atropine in controlling the progression of myopia.Methods: This work was done through the data search from PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The Cochrane Handbook was also used to evaluate the quality of these included studies. In addition, a meta-analysis was performed using Revman5.3 software.Results: A total of 10 randomized controlled trials (RCTs) were included. Myopia progression was mitigated in the atropine treatment group, with MD = -0.80, 95% CI (-0.94, -0.66). There was a statistical difference between 0.05%, 0.5%, and 1.0% atropine (P = 0.004). In addition, axial elongation was slowed, with MD = -0.26, 95% CI (-0.33, -0.18).Conclusion: The effect of atropine in controlling the progression of myopia was dose-dependent. A 0.05% atropine was most likely to be the optimal dose.

show abstract

Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results

Abstract: During the 1-year follow-up, the combination of OK and atropine 0.01% ophthalmic solution was more effective in slowing axial elongation than OK monotherapy in children with myopia.

Cited by 90 publications

References 47 publications

Efficacy and Safety of Atropine to Control Myopia Progression: A Systematic Review and Meta-analysis

Efficacy and Safety of Atropine to Control Myopia Progression: A Systematic Review and Meta-analysis

Myopia Control 2020: Where are we and where are we heading?

Efficacy and Safety of Atropine to Control Myopia Progression: a Systematic Review and Meta-analysis

Contact Info

Product

Resources

About